University of Missouri, Columbia.
Correspondence: Tyler W. Myroniuk, PhD, School of Health Professions, Department of Public Health, University of Missouri-Columbia, 826 Lewis Hall, Columbia, MO 65201 ([email protected]).
In fall 2020, the University of Missouri CARES funding and other internal funding sources, as well as support from SIEMENS Healthineers, funded the MU Study of Seropositivity and Risk for SARS-CoV-2 and COVID-19. The study was reviewed and approved under University of Missouri IRB protocol #2028427.
The authors thank Mark McIntosh, Stevan Whitt, John Middleton, and the MU Incident Command Team, who foresaw the importance of this study and facilitated its creation. The authors also could not have successfully collected these data without the support of Student Information Services and Human Resources to supply randomly selected e-mail lists (Chase Hickman, Allen Johanning, Jeremy Wiebold), IT staff, who helped with appointment and Web site development (Lei Jiang), the team of consenters (Ifeolu David, Brady Chung, Emma Foust, Emily Perisho, Kamilla Sarvestani, Peyton Kusgen, Megan Polniak, Sarah Simmons, Tess Willemse), the clinical staff (Julie Stilley, Shannen Woodrey, Allison Thomas, Collin Welch, Ella Bochenski, Madison Enright, Madison Hassler, Tess Goldenberger), their Student Health partners (Jamie Shutter, Scott Henderson), the REDCap survey and data collection design team (Ifeolu David, Abu Mosa, Vasanthi Mandhadi), the risk survey and qualitative study teams (Ifeolu David, Michelle Teti, Yerina Ranjit, Chrystal Hamilton, Haejung Shin), and the immunology laboratory team (Alexander Earhart, Mark Daniels, Yue Guan, Kim Laffey, Adam Schrum). The authors also thank the students, staff, and faculty in the University of Missouri community who participated in this study.
The authors declare no conflicts of interest.
